SGLT2i are now recommended for patients with type 2 diabetes mellitus (T2DM) and showed glycemic and non-glycemic benefits in T1DM as well, including improved glycemic control and glycemic variability, decreased insulin dose requirement, and blood pressure and body weight reduction [5,6]. The gene discussed is INS; the disease is type 2 diabetes mellitus.